Verve
also invests · investor profileFounded 2010 · 63 employees on LinkedIn · 1 known investors
Verve Ventures is a European venture capital investor backing pre-seed and seed deep tech companies.
Also known as Investiere · Verve Capital Partners AG · Verve Ventures
Investors · 1
Company profile
researched Aug 2026Verve, operating as Verve Ventures and legally as Verve Capital Partners AG, is a venture capital investor focused on European deep tech. The firm invests at pre-seed and seed stage with initial ticket sizes of EUR 1-5 million and backs founders based in Europe. Its investment activity is organised around three stated themes: resilience in energy and resources, the future of computing, and frontiers in health and bio, the latter covering the convergence of biology, engineering and data in healthcare and life sciences.
Alongside direct investing, Verve runs an online platform through which investors access startup opportunities, with accounts, application flows and portfolio data (referred to as Investiere in its privacy documentation). The firm has secured a securities firm license from the Swiss financial regulator FINMA, which it describes as providing a regulated bridge for private and professional investors into European technology investments. Verve also publishes insights and hosts thesis webinars on its three investment topics.
Business model
Verve invests venture capital in early-stage European deep tech companies and provides investors with access to those investments through its regulated platform, with user accounts, KYC onboarding and portfolio tracking.
Traction
Portfolio companies disclosed include Metafuels (sustainable aviation fuel), Q.ant (optical processors for AI workloads), C12 (carbon nanotube quantum processors), Neustark (CO2 storage in concrete), Ecorobotix (precision spraying), Orakl Oncology (oncology drug discovery), tozero (lithium-ion battery recycling), an AI-powered warehouse drone company, Aylight (chip-scale lasers for datacenter interconnects) and Ikerian, marked as an exit. Portfolio company Memo Therapeutics agreed to be acquired by Ipsen for a potential consideration above EUR 700 million.
Latest developments
Verve announced Aylight, an ETH Zurich spin-off building chip-scale frequency-comb lasers for datacenter interconnects, as a new portfolio company; secured a FINMA securities firm license; reported that portfolio company Memo Therapeutics agreed to be acquired by Ipsen; and scheduled 2026 thesis webinars on health and bio (May 27, 2026), energy and resources (September 2, 2026) and future of computing (December 2, 2026).
▸Full profile — market position, technology, go-to-market, geography
Market position
Positions itself as a deep tech specialist investor at the pre-seed and seed stage in Europe and, following its FINMA securities firm license, as a regulated financial institution in Switzerland.
Technology
Operates a website and platform with investor login, application intake, business management tools, startup research and portfolio data, supported by third-party analytics and infrastructure services.
Go-to-market
Reaches founders through an online application process and reaches investors through its platform, published insights and thematic webinars on its investment theses.
Two sides: European deep tech founders at pre-seed and seed stage seeking EUR 1-5 million initial tickets, and investors including family offices, wealth managers, institutions, founders and senior executives.
Geography
Focused on European founders; the operating entity Verve Capital Partners AG is Swiss and holds a FINMA license, and portfolio companies include Zurich-based ventures.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsVerve announced a new portfolio company, Aylight, a Zurich-based ETH spin-off developing chip-scale lasers that emit a frequency-modulated comb of many precisely spaced wavelengths for datacenter interconnects.
Memo Therapeutics AG entered a definitive agreement to be acquired by Ipsen for a total potential consideration in excess of EUR 700 million, advancing the antibody potravitug toward pivotal trials for kidney transplant patients.
Verve obtained a securities firm license from Swiss regulator FINMA, positioning the firm among regulated financial institutions in Switzerland and providing a structured channel for private and professional investors to access European technology investments.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 1
primary sources listed
- Verveverve.vc · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Verve do?
- Verve Ventures is a European venture capital investor backing pre-seed and seed deep tech companies.
- Who are Verve's investors?
- Verve's investors include Metavallon VC.